– USA, CA – CohBar, Inc. (NASDAQ: CWBR), a clinical-stage biotechnology company today announced the appointment of Dr. Effie Tozzo (Ph.D.) to its Board as an Independent Director, effective July 11, 2022, bringing extensive research and development experience at both established pharmaceutical and innovative biotechnology companies.
“We are delighted to add Dr. Tozzo to our Board and will tap into her considerable expertise in advancing preclinical assets to the clinic and building robust pipelines. Effie’s deep research and development experience will provide useful insights as we continue to look to the mitochondrial genome as a potential source for novel therapeutics. Her perspective will help inform the continued progress in our preclinical and clinical programs,” said Board Chairman, David Greenwood.
About Dr. Effie Tozzo
Dr. Effie Tozzo is currently CSO at Avilar Therapeutics, a biotechnology company creating a broad and diverse pipeline of extracellular protein degraders as first-in-class medicines for the treatment of serious diseases. As a leader in drug discovery, translational sciences and medicine, Dr. Tozzo has over 26 years of experience in leadership roles in biotech/startups and large pharma organizations. She has initiated and progressed discovery programs to the clinic by building and effectively leading teams in preclinical biology, chemistry, pharmacology, DMPK, safety and biomarker studies in various disease indications.
Over the past 8 years, Dr. Tozzo served at Cellarity (a Flagship Pioneering company) as SVP, Drug Development and Head of R&D and as SVP, Translational Sciences at Mitobridge, building teams and strong program pipelines, scientifically leading financing campaigns and pharma partnerships and supporting clinical teams through Phase 1 and clinical proof of concept studies.
“I look forward to joining CohBar’s Board at this exciting time as the company is working towards moving a second candidate into the clinic,” said Dr. Tozzo. “CohBar’s Mito+ platform and novel approach to drug discovery have potential utility in a wide range of therapeutic indications. I am pleased to contribute to the advancement of the company’s pipeline to benefit patients in need of new therapies to treat life-threatening conditions like IPF.”
Earlier in her career, Dr. Tozzo held leading positions at Merck, Roche, BMS, Millennium, Chiron and ErgoScience. She received her PhD in Molecular and Cellular Endocrinology from the University XI in Paris, France, completed her post-doctoral training in the Endocrine Division at Beth Israel/Harvard Medical School in Boston and has authored over 40 peer-reviewed publications and patents.
About CohBar
CohBar is a clinical-stage biotechnology company leveraging the power of the mitochondria and the peptides encoded in its genome to develop potential breakthrough therapeutics targeting chronic and age-related diseases with limited to no treatment options. CohBar has assembled the leading position in exploring the mitochondrial genome and its utility for the development of novel therapeutics, including world-renowned expertise in mitochondrial biology, a broad intellectual property estate, key opinion leaders and disciplined drug discovery and development processes. CohBar is utilizing its Mito+ platform to identify and develop modified versions of natural peptides called analogs to treat a variety of serious conditions, with a focus on diseases involving inflammation and fibrosis.
For more information: https://www.cohbar.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.